Stock	Buy / Short	Thesis	Current Price	Target Price
Dr. Peper Snapple Group, Inc.	BUY	Dr. Pepper Snapple Group has positioned itself to gain market share in a competitive industry. Its expansion to Mexico and Latin America, both rapidly growing markets, will increase sales and stock value. Additionally, DPS's equity purchase of BodyArmor, a rapid growth sports drink company, will help drive future growth. DPS has also demonstrated a commitment to increasing shareholder value, both through stock repurchases and growing dividend payouts. DPS is a low-risk investment that can be counted on for consistent growth and returns. It is currently undervalued, and is a recommended a buy with a target price of $99.74. This, when coupled with the dividend payout is a one-year return of around 15%.	$ 90.35	$ 93.74
Luminex Corporation	BUY	Luminex is a company with a well-managed capital structure that has acknowledged a quick growth of their assets and revenues during the past five years. In addition to expanding their product line through research and development the company also seeks partnerships with other organizations in order to have their researches sponsored and reduce their costs overall. In 2012 Luminex has entered a partnership with the Defense Threat Agency (D.T.A.) of the United-States to research and develop a defense project for the United-States government. This partnership may become an opportunity of a true and stable source of revenue for the company if it succeeds. The company has an impressive capital structure considering the industry they operate in which often requires an important amount of debt to be able to operate efficiently. Luminex has a current debt to Equity ratio of 0.09 and does not carry any long-term debt. This debt management increases the capacities of the firm to pursue business without being burdened by too much debt. Luminex Corporation also has an effective cost management that allows them to generate appropriate revenues. The operating income of the firm accounts for 16% of the revenues despite the fact that 21% of the total operation costs are used for the Research & Development of new or existing products. This cost management is even more effective given the fact that the company did not have any interest expenses in the past years.	$ 19.24	$ 23.19

Lockheed Martin Corporation	BUY	Lockheed Martin is the world's largest defense contractor, but it is also the most diversified and the most prepared for future growth among all the aerospace & defense companies. The defense industry is expected to return to a minimum of 3% growth in 2016, given the recent rise in global threats, and the increase in military expenditures in the U.S. and in key foreign nations. Due to its top-of-the-art and renowned products, LMT has secured future growth in product and service sales. LMT has succeeded to place itself as one of the top performers of the industry. The company is also committed in innovation and emerging technologies that have the potential to bring important sales to the company or even to create new markets. In 2015, the company generated a record $5.1 billion from operations and returned $5 billion to shareholders via an increasing dividend and an increasing share repurchase program strategy. The company also operated two major changes in its portfolio. First, it acquired for $9 billion Sikorsky, which is the largest helicopter manufacturer. This acquisition added $16 billion in backlog to LMT to reach a record of $100 billion of backlog. The second strategic move was the decision to sell a part of its Information Services & Global Services to Leidos for $5 billion. The company decided to separate and combine this business with Leidos to create a more diversified competitor positioned for growth. Indeed, this market was becoming more and more competitive, and margins were decreasing and expected to decrease. The stock performance over time is pretty strong. It outperformed the industry and the market, and is showing good resistance during market selloffs. LMT appeared to be a very valuable investment to hold on the long term.	$ 220.91	$ 243.00

The Sherwin-Williams Co.	BUY	Sherwin-Williams is already the leader in the United States in terms of paint sales, and looks to grow market share even further in 2016. The company has enjoyed a decrease in the cost of inputs thanks to many of the key components in coatings being derived from petrochemicals. The cost of inputs for the industry tends to lag behind changes in the price of oil. While the rebound may have already begun for the price per barrel, SHW should see a lower cost of materials for the remainder of the year, barring any unusual jumps in the price of oil. Thanks to this decrease in cost of goods sold, and an improvement in sales for three of the four business segments under the Sherwin-Williams brand, margins have improved greatly in 2015 and according to the company's financial statements and earnings calls, management is working hard to continue these improvements in 2016. Another key component of the company's improvements is continued acquisitions. Over the past five years the firm has acquired several small market share competitors in order to move into new markets, especially the southern and south-eastern United States. By purchasing competition rather than simply opening a new Sherwin-Williams location, it has made accessing new customers much easier and more effective. In the professional paint contracting business the majority of cost is in labor. Contractors are willing to pay a premium for SHW products because they beat competition in many aspects such as coverage, durability, cure time, and ease of application. These benefits combined with entry into new markets are driving sales of Sherwin-Williams paints up consistently. Another important element of the business that is estimated to grow in 2016 is housing starts and sales. Contractors have grown to trust the product, and now as the housing market continues to grow and	$ 288.69	$ 310.83
Tower International Inc.	BUY	Tower International is currently set up to see an increase in its value as its inputs of steel and aluminum have seen a reduction in price. This, with a growing demand for vehicles, will help drive value for TOWR. TOWR has further created value be selling off facilities that do not produce high enough margins. This is an attempt to improve margins in the future. Tower International has worked to have a diverse customer base to give them bargaining power rather than their customers. Tower International is considered a BUY at the price of $25.81. Its one-year target is $32.16 which is an upside potential of 24.6%.	$ 25.81	$ 32.16

Morningstar Inc.	BUY	Morningstar is not a skyrocketing stock but a steady increasing stock which with its low beta of 0.44 and its constant value creation with a ROIC/WACC of around 2.60 makes the company a sure buy pick for anyone who is looking for a profit. Because the founder of the company has a majority ownership in it, he is seeking to increase its value and stock price through dividends issuance and stocks repurchase. The increase in revenue and growth cumulated to the company outperforming its industry prove that the company will reach a higher price.	$ 83.93	$ 96.00
AMAG Pharmaceuticals	BUY	AMAG Pharmaceuticals has positioned themselves with a high potential to become a major player within the biotechnology industry. The recent acquisitions of Lumara Health Inc. in November 2014, and CBR in August 2015, has generated exponential revenue growth for AMAG pharmaceuticals. These acquisitions also provide a catalyst for long term value creation for AMAG Pharmaceuticals. Such value creation has the potential to create substantial value for the shareholders of AMAG. In January 2016, the board of directors for AMAG Pharmaceuticals authorized a program to repurchase up to $60 million in shares of common stock. As an analyst this suggests that the board for AMAG Pharmaceuticals believes their stock is undervalued in the market. The biotechnology industry as a whole has also demonstrated high growth, which is likely to continue in the near future.	$ 21.63	$ 33.80
Chipotle Mexican Grill	SHORT	Investor confidence and consumer confidence are currently taking a severe hit for Chipotle. This is because of the E. coli outbreak associated with Chipotle which occurred between December and February. Chipotle currently market that they serve only fresh ingredients. This is largely due to the very strict requirements there suppliers must comply with. The whole point of Chipotle is that it is clean. And recently they have begun to show us that they are not. The litigations have also been accruing recently; in direct relation to the health concerns. This outbreak will continue to hinder growth for the foreseeable future due to the direct effects it will have on financials. Diminishing the operating and gross margins as well as forecasted growth. Because of all of these concerns and issues it is likely that if another health issue occurred at Chipotle, then a highly unfavorable situation would most likely come about for Chipotle.	$ 455.37	$ 337.00

Foot Locker Inc.	BUY	In recent years, there has been a health and fitness boom within the United States. The number of gym memberships have been increase steadily over time. With this increase, it creates a greater market for Foot Locker to supply for. Not only that, but current fitness members typically purchase new shoes for their athletic activities every year or so. This gives Footlocker a sustainable market going forward. The Summer Olympics is also another opportunity for Foot Locker to grow and create value within the very near future. The Summer Olympics creates awareness of fitness to consumers and also gives Foot Locker additional merchandise. In 2012 when the last Summer Olympics occurred, Footlocker experienced their greatest increase in revenue from the previous year at 11.4%, their greatest in recent history.	$ 65.22	$ 81.41
Advanced Micro Devices	SHORT	Advanced Micro Devices is in the semiconductor industry, with reported revenues of $3,991 million in 2015. It is being reported that Intel is going to ink a deal to work with Advanced Micro Devices in the coming months, for AMD's patents. Intel currently has a deal with Advanced Micro Devices' rival, Nvidia, but the contract is set to expire on March 17, 2017. AMD has a competitive product at a cheaper cost than Nvidia, which makes it an attractive option for Intel. Nvidia has been reporting $66 million in licensing revenue per quarter from Nvidia. This is a big reason why the stock price has gone up over 30% over the last few months. Even though it is likely that Intel will sign AMD, there is still a chance that they decide to stay with Nvidia, which will lead to the stock being severely overvalued. Also, the move wouldn't happen until March 17, 2017 when the contract is set to expire with Nvidia, which means for the next year they will see their revenue growth grow only slightly if at all. Although they have the possibility to increase their revenue if the Intel signing goes through, they have seen a drastic decrease in their revenue from 2014 to 2015. In 2014 they reported revenue of $5,506 million to only $3,991 million in 2015. This is a decrease of over 27.5% from year to year. This is due to the fact that the personal computer industry is declining along with the fact that they are losing market share to Intel. In 2006, they had about 50% market share of the CPU industry, while in 2016 they had only about 20% of the market share. This is due to the fact that there are many competitors, mainly Intel who is taking away market share from Advanced Micro Devices, and thus leading to reduced levels of revenue.	$ 2.93	$ 2.30